CVS
CVS Health Corporation
Healthcare · Healthcare Plans · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The overall model score of 37.6/100 reflects a weighted composite in which three of six sub-scores — profitability (4.0), growth (6.0), and theme (0.0) — are critically low, pulling the total well below the midpoint of the scoring range.
- The best-fit profile score of 43.3 under dividend income is the only goal profile where CVS reaches above-average relevance, driven primarily by the 13.8/20 dividend sub-score, but even this is insufficient to push the composite above the 'Monitor Only' threshold.
- The financial health sub-score of 10.0/20 reflects elevated leverage from acquisition activity, which the model penalizes as it limits balance sheet resilience and constrains future capital allocation optionality.
Why Not Higher
- The profitability sub-score of 4.0/20 — the weakest individual metric — directly reflects the severe margin deterioration visible in the FY2025 10-K, including pressure from medical loss ratios in the Aetna segment and restructuring charges, and this single metric is one of the most heavily weighted in the model.
- The theme score of 0.0/20 means CVS received no credit for macro theme alignment, which is a significant missed opportunity in the scoring model and reflects that the filing-derived data does not map to qualifying structural growth themes tracked by the model's criteria.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
CVS Health Corporation is a vertically integrated U.S. healthcare company operating across three major segments: pharmacy benefits management (Caremark), retail and specialty pharmacy, and health insurance (Aetna). The company serves tens of millions of Americans through its retail pharmacy network, mail-order pharmacy, and health plan offerings, making it one of the most structurally complex healthcare enterprises in the country. Its FY2025 10-K filing underpins a composite model score of 37.6/100, reflecting a business under significant operational and financial strain despite its scale. The score is dragged down sharply by weak profitability (4.0/20) and negligible growth momentum (6.0/20 growth, 8.8/20 momentum), suggesting that recent revenue and earnings trajectories have deteriorated meaningfully in the filing period. The financial health sub-score of 10.0/20 further signals elevated leverage and constrained balance sheet flexibility, consistent with the capital requirements of integrating Aetna and Oak Street Health acquisitions. The dividend sub-score of 13.8/20 is the model's strongest reading for CVS and anchors the best-fit profile as dividend income, indicating that free cash flow coverage of the dividend and dividend per share history remain relatively intact even as earnings compress. The central research tradeoff is between a durable, large-scale business with a meaningful dividend track record and a profitability profile that is currently under pressure from medical cost ratios, restructuring, and integration costs — producing a 'Monitor Only' label rather than an actionable research candidate.
Plain English
CVS Health runs pharmacies, manages prescription drug benefits for employers and insurers, and sells health insurance through Aetna — it's essentially a one-stop healthcare company. The model score of 37.6 out of 100 tells researchers that while CVS still generates enough free cash flow to support its dividend, its profitability and growth metrics from its most recent annual filing are quite weak. The High risk rating reflects that the company's financials show meaningful leverage and shrinking margins, which could put pressure on future payouts or operational flexibility. This is currently a 'Monitor Only' research label, meaning the model does not flag it as a strong candidate under most goal profiles.
Bull Case vs. Bear Case
Bull Case
- The dividend sub-score of 13.8/20 — the highest in CVS's score breakdown — indicates that free cash flow payout coverage and dividend per share history remain relatively supportive, making it a notable candidate within dividend income research screens.
- CVS's vertically integrated model spanning PBM, retail pharmacy, and health insurance creates structural scale advantages that are reflected in the company's balance sheet size component within the financial health sub-score.
- The momentum sub-score of 8.8/20, while modest, suggests some quarterly stabilization in revenues or earnings relative to deeper deterioration, which could indicate the worst of the margin compression cycle may be partially factored into the filing data.
Bear Case
- The profitability sub-score of just 4.0/20 is critically low, indicating that net margin, operating margin, and return on assets derived from the FY2025 10-K filing are severely compressed relative to the model's scoring universe.
- The growth sub-score of 6.0/20 signals that year-over-year revenue, net income, and EPS growth are all weak or negative in the filing period, reflecting the financial drag from rising medical costs and ongoing integration expenses.
- The financial health sub-score of 10.0/20 points to elevated leverage ratios and insufficient interest coverage headroom, which limits CVS's operational and financial flexibility if business conditions deteriorate further.
What Could Change the Picture
Bullish Triggers
- A meaningful recovery in the profitability sub-score — driven by demonstrated improvement in net and operating margins in a subsequent 10-K filing — would be the single largest catalyst for a higher composite model score.
- Evidence in a future filing of declining leverage ratios and improved interest coverage, indicating successful debt reduction post-acquisition integration, would strengthen the financial health sub-score and reduce the High risk rating.
Bearish Triggers
- Any reduction or suspension of the dividend per share in a future filing would directly damage the 13.8/20 dividend sub-score, which is currently the primary anchor of CVS's research relevance under the dividend income profile.
- Further deterioration in quarterly revenue or earnings trends reflected in a future filing would push the momentum sub-score below its current 8.8/20 reading and signal accelerating fundamental weakness rather than stabilization.
Red Flags
- The combination of a 4.0/20 profitability score and 10.0/20 financial health score in the same filing period is a material concern, as compressed margins alongside high leverage reduce the company's capacity to service debt and sustain dividends simultaneously.
- A theme score of 0.0/20 indicates that the model identified zero qualifying macro theme exposures in the filing, suggesting CVS lacks near-term structural tailwinds that would support a re-rating of its risk profile.
- The growth sub-score of 6.0/20 combined with weak profitability raises the risk that the current dividend per share level could face scrutiny if free cash flow generation deteriorates from FY2025 levels.
Risk Profile
High RiskThe High risk rating for CVS reflects the concurrent presence of elevated financial leverage, severely compressed profitability metrics, and negative or negligible growth in its FY2025 annual filing — a combination that the model treats as a materially heightened risk profile regardless of company size. For a company with CVS's debt load and integration obligations, sustained margin pressure raises the risk that financial flexibility could erode faster than revenue growth can compensate.
Key Catalysts to Watch
The key filing-derived factors to monitor for CVS are the trajectory of its medical loss ratio within the Aetna segment, which is the primary driver of the profitability collapse visible in the current score, and the company's pace of debt reduction relative to its free cash flow generation, which underpins both the dividend sub-score and financial health assessment in future 10-K filings.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.